Other languages 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Real-time Estimate Cboe BZX Other stock markets 10:21:36 2024-04-25 am EDT			5-day change	1st Jan Change
23.34 ^USD	-3.77%		-6.12%	+14.82%

Apr. 15	Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	MT
Apr. 15	RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing	Apr. 04
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis	Mar. 28
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis	Mar. 28
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium? 2024	Feb. 12
4d Molecular Therapeutics Insider Sold Shares Worth $737,788, According to a Recent SEC Filing	Feb. 08
4D Molecular Therapeutics Launches $250 Million Stock Offering	Feb. 05
4D Molecular Therapeutics Shares Surge on Positive Data From Phase 2 Study of Wet AMD Drug Candidate	Feb. 05
Top Midday Gainers	Feb. 05
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	Feb. 05
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell	Feb. 05
Top Premarket Gainers	Feb. 05
4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150	Feb. 03
4D Molecular Therapeutics' Treatment Candidate for Cystic Fibrosis Gets FDA Rare Pediatric Disease Designation	Jan. 23
4D Molecular Therapeutics Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease	Jan. 23
4D Molecular Therapeutics, Inc. Announces Management Changes	Jan. 04
4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates	Jan. 04
4D Molecular Therapeutics and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases	Jan. 03
4D Molecular Therapeutics, Arbor Biotechnologies Form Central Nervous System Disease Partnership	Jan. 03
4D Molecular Therapeutics Shares Rise as Wet AMD Treatment Candidate Gets FDA's RMAT Designation	Dec. 21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Other languages

Filters